Lakcid Entero

Saccharomyces boulardii, the active ingredient in Lakcid Entero, is a probiotic presented as an oral preparation for oral use. It is used to help manage diarrhea associated with antibiotics, infections, and travel, and to support gut health in adults and children.

GNH USA supplies Lakcid Entero as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lakcid Entero is a probiotic that acts on the gastrointestinal tract to restore microbial balance and reduce diarrheal symptoms. - Antibiotic‑associated diarrhea: helps re‑establish normal gut flora and shortens the duration of loose stools. - Clostridioides difficile infection (adjunct therapy): supports conventional treatment by limiting pathogen overgrowth. - Acute infectious diarrhea: reduces stool frequency and improves stool consistency during bacterial or viral gastroenteritis. - Travelers’ diarrhea: aids in maintaining intestinal homeostasis when exposure to unfamiliar pathogens occurs.

Lakcid Entero is generally well tolerated, but some users may experience mild reactions.

Common Side Effects: - Abdominal bloating: mild, transient increase in gas. - Flatulence: excess intestinal gas. - Nausea: occasional feeling of queasiness. - Mild constipation: occasional reduced bowel movements.

Serious or Rare Side Effects: - Fungemia: rare bloodstream infection, primarily in severely immunocompromised patients. - Allergic reaction: rash, itching, or swelling that may require medical attention.

Before using Lakcid Entero, consider the following precautions. - Immunocompromised patients: assess risk of opportunistic infection before administration. - Central venous catheters: avoid use if catheter is present due to potential translocation risk. - Pediatric use: follow prescriber guidance for children, especially infants. - Concomitant antifungal therapy: monitor for reduced probiotic efficacy. - Store below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Lakcid Entero may interact with certain medications, requiring attention to avoid reduced effectiveness or safety concerns.

Major Interactions (Avoid): - Systemic antifungal agents (e.g., fluconazole): may inhibit probiotic yeast viability. - Broad‑spectrum antibiotics taken concurrently: can diminish probiotic colonisation.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., corticosteroids, biologics): increase risk of systemic infection, monitor patient closely. - Antidiarrheal agents (e.g., loperamide): may alter gut motility, affecting probiotic distribution.